2nd Annual Hemophilia Drug Development Summit
Evvnt Promotion / evvnt
Archivo
20.08.2019 - 22.08.2019 Wyndham Boston Beacon Hill, 5 Blossom Street, 02114 Boston, USA
Time: 8:00 am - 5:00 pm
Temas de la conferencia
Given the excitement and anticipation of increasingly more promising prophylactic treatments and gene therapies, the 2nd Annual Hemophilia Drug Development Summit, once again unites leading pharma, biotech and academic KOLs working to translate and clinically develop longer acting and more efficacious therapies to overcome significant unmet medical need and hemophilia and other bleeding disorders.
Given the excitement and anticipation of increasingly more promising prophylactic treatments and gene therapies, the 2nd Annual Hemophilia Drug Development Summit, once again unites leading pharma, biotech and academic KOLs working to translate and clinically develop longer acting and more efficacious therapies to overcome significant unmet medical need and hemophilia and other bleeding disorders.
Organizador profesional (PCO)
Hanson Wade
Hanson Wade
Observaciones
Brochure: https://go.evvnt.com/411348-2?pid=4832
Speakers: Howard Levy, Chief Medical Officer, Catalyst Biosciences, H. Trent Spencer,President, Expression Therapeutics
Brochure: https://go.evvnt.com/411348-2?pid=4832
Speakers: Howard Levy, Chief Medical Officer, Catalyst Biosciences, H. Trent Spencer,President, Expression Therapeutics
Información e inscripción:
https://go.evvnt.com/411348-0?pid=4832
Mr. Ilektra Stouka
Salud Pública, Servicios de salud
Idioma
Inglés
Inglés
Cuota del Congreso
USD 3.697,00
(USD 1499.0 - USD 3697.0)
USD 3.697,00
(USD 1499.0 - USD 3697.0)
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."